Menu Search

Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments

Y-mAbs Therapeutics, a privately held immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced the closing of a private placement raising USD 50 million. HBM Healthcare Investments, who led the round, contributed USD 20 million in this financing. Dr. Michael Buschle of HBM Partners will join the Board of Y-mAbs.